Ascites, refractory ascites and hyponatremia in cirrhosis
- PMID: 28533908
- PMCID: PMC5421465
- DOI: 10.1093/gastro/gox010
Ascites, refractory ascites and hyponatremia in cirrhosis
Abstract
Ascites is the most common complication related to cirrhosis and is associated with increased morbidity and mortality. Ascites is a consequence of the loss of compensatory mechanisms to maintain the overall effective arterial blood volume due to worsening splanchnic arterial vasodilation as a result of clinically significant portal hypertension. In order to maintain effective arterial blood volume, vasoconstrictor and antinatriuretic pathways are activated, which increase overall sodium and fluid retention. As a result of progressive splanchnic arterial vasodilation, intestinal capillary pressure increases and results in the formation of protein-poor fluid within the abdominal cavity due to increased capillary permeability from the hepatic sinusoidal hypertension. In some patients, the fluid can translocate across diaphragmatic fenestrations into the pleural space, leading to hepatic hydrothorax. In addition, infectious complications such as spontaneous bacterial peritonitis can occur. Eventually, as the liver disease progresses related to higher portal pressures, loss of a compensatory cardiac output and further splanchnic vasodilation, kidney function becomes compromised from worsening renal vasoconstriction as well as the development of impaired solute-free water excretion and severe sodium retention. These mechanisms then translate into significant clinical complications, such as refractory ascites, hepatorenal syndrome and hyponatremia, and all are linked to increased short-term mortality. Currently, liver transplantation is the only curative option for this spectrum of clinical manifestations but ongoing research has led to further insight on alternative approaches. This review will further explore the current understanding on the pathophysiology and management of ascites as well as expand on two advanced clinical consequences of advanced liver disease, refractory ascites and hyponatremia.
Keywords: ascites; cirrhosis; hyponatremia; portal hypertension.
Figures
Similar articles
-
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.J Hepatol. 2000;32(1 Suppl):157-70. doi: 10.1016/s0168-8278(00)80423-7. J Hepatol. 2000. PMID: 10728802 Review.
-
Management of ascites and hepatorenal syndrome.Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23. Hepatol Int. 2018. PMID: 28836115 Review.
-
Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites.Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):607-22. doi: 10.1016/s1521-690x(03)00052-6. Best Pract Res Clin Endocrinol Metab. 2003. PMID: 14687592 Review.
-
Pathophysiology, diagnosis and treatment of ascites in cirrhosis.Ann Hepatol. 2002 Apr-Jun;1(2):72-9. Ann Hepatol. 2002. PMID: 15115971 Review.
-
Cirrhosis and Portal Hypertension: How Do We Deal with Ascites and Its Consequences.Med Clin North Am. 2023 May;107(3):505-516. doi: 10.1016/j.mcna.2022.12.004. Epub 2023 Feb 20. Med Clin North Am. 2023. PMID: 37001950 Review.
Cited by
-
Management of refractory cirrhotic ascites: challenges and solutions.Hepat Med. 2018 Jul 3;10:55-71. doi: 10.2147/HMER.S136578. eCollection 2018. Hepat Med. 2018. PMID: 30013405 Free PMC article. Review.
-
Diagnostic utility of the serum-ascites albumin gradient in Mexican patients with ascites related to portal hypertension.JGH Open. 2020 Aug 8;4(5):838-842. doi: 10.1002/jgh3.12404. eCollection 2020 Oct. JGH Open. 2020. PMID: 33102752 Free PMC article.
-
Current approaches to the management of patients with cirrhotic ascites.World J Gastroenterol. 2019 Jul 28;25(28):3738-3752. doi: 10.3748/wjg.v25.i28.3738. World J Gastroenterol. 2019. PMID: 31391769 Free PMC article. Review.
-
Gastro‑oesophageal reflux disease in liver cirrhosis: Possible pathogenesis and clinical intervention (Review).Exp Ther Med. 2023 Jul 12;26(3):414. doi: 10.3892/etm.2023.12113. eCollection 2023 Sep. Exp Ther Med. 2023. PMID: 37559931 Free PMC article. Review.
-
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.Immunotherapy. 2024;16(12):821-828. doi: 10.1080/1750743X.2024.2370231. Epub 2024 Jul 17. Immunotherapy. 2024. PMID: 39016058 Free PMC article.
References
-
- Ge PS, Runyon BA.. Treatment of patients with cirrhosis. N Engl J Med 2016;375:767–77. - PubMed
-
- Everhart JE, Ruhl CE.. Burden of digestive diseases in the United States. Part I: Overall and upper gastrointestinal diseases. Gastroenterology 2009;136:376–86. - PubMed
-
- Planas R, Montoliu S, Balleste B. et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4:1385–94. - PubMed
-
- D’Amico G, Garcia-Tsao G, Pagliaro L.. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217–31. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials